US EditionPublished • loading... • Updated
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented results from multiple clinical studies on TROP2 ADC sacituzumab tirumotecan at the 2025 CCHIO Congress.
- Professor Fang Wenfeng reported promising clinical activity of sac-TMT in advanced non-small cell lung cancer with uncommon EGFR mutations.
- The combination of sac-TMT and tagitanlimab showed promising antitumor activity in treatment-naive advanced non-squamous non-small cell lung cancer patients, according to Professor Fang Wenfeng.
- Kelun-Biotech is conducting over 30 clinical studies across various cancer types, including lung cancer and breast cancer.
Insights by Ground AI
59 Articles
59 Articles
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
CHENGDU, China, Nov. 9, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA), the Tengchong Science…
Coverage Details
Total News Sources59
Leaning Left6Leaning Right7Center20Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
L 18%
C 61%
R 21%
Factuality
To view factuality data please Upgrade to Premium
